Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure
Tempus AI expands its collaboration with Moderna and Merck to support sample collection and NGS services for intismeran autogene and Keytruda.
Stocks · News reference
Personalis Q2 EPS $(0.30) Misses $(0.27) Estimate, Sales $22.357M Beat $16.783M Estimate
Personalis (NASDAQ:PSNL) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.27) by 15.38 percent. This is a 30.43 percent decrease over losses of $(0.23) per share from the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Personalis, Inc. (PSNL)
Filed: 2026-10-06 AccNo: 0001193125-26-415547 Size: 156 KB Item 8.01: Other Events
This Gentex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday
Analysts downgraded Gentex, Personalis, Goosehead Insurance, cutting ratings and several price targets.
BTIG Downgrades Personalis to Neutral
BTIG analyst Mark Massaro downgrades Personalis (NASDAQ:PSNL) from Buy to Neutral.